Down-regulation of neutrophil gelatinase-associated lipocalin in head and neck squamous cell carcinoma correlated with tumorigenesis, not with metastasis.

To examine the significance of the Neutrophil gelatinase-associated lipocalin (NGAL) in diagnosing head and neck squamous cell carcinoma (HNSCC) and predicting regional metastasis. We first used GEO dataset to analyze the NGAL gene expression in HNSCC. Then, we summarized the characteristics of patients retrospectively selected in clinic. Expression of NGAL protein in human HNSCC tumor, lymph node and normal samples were analyzed using immunohistochemistry. Next, we further investigated the NGAL expression in a tissue microassay to analyze the relationship between NGAL protein expression and TNM stage. Finally, we tested the NGAL protein expression in head and neck cancer cell lines. Analysis of GEO dataset concluded that NGAL gene expression in HNSCC was lower than that in normal tissue (P<0.01). There was no statistically significant difference of NGAL gene expression between T-stage and N-stage (P>0.05). NGAL protein expression in tumor was lower than that in normal tissue (P<0.01). There was no statistically significant difference of NGAL protein expression between metastasis group and non-metastasis group (P>0.05). Expression of NGAL protein was not correlated with TNM stage of HNSCC. Aggressive HNSCC cell lines have lower NGAL protein expression. Our data demonstrated that the expression of NGAL protein was correlated with tumorigenesis of HNSCC, but not with regional metastasis. It may serve as a novel biomarker for prognostic evaluation of patients with HNSCC.

[1]  S. Willems,et al.  Nodal metastasis and survival in oral cancer: Association with protein expression of SLPI, not with LCN2, TACSTD2, or THBS2 , 2015, Head & neck.

[2]  Marsha A. Moses,et al.  Urinary ADAM12 and MMP-9/NGAL Complex Detect the Presence of Gastric Cancer , 2015, Cancer Prevention Research.

[3]  B. Cho,et al.  A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer , 2014, Naunyn-Schmiedeberg's Archives of Pharmacology.

[4]  J. McCubrey,et al.  Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer , 2014, Oncotarget.

[5]  Shun-Fa Yang,et al.  Knockdown of lipocalin‐2 suppresses the growth and invasion of prostate cancer cells , 2013, The Prostate.

[6]  N. Zengi̇n,et al.  Evaluation of renal function using the level of neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[7]  C. Butterfield,et al.  Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  C. H. Lin,et al.  Role of lipocalin 2 and its complex with matrix metalloproteinase-9 in oral cancer. , 2012, Oral diseases.

[9]  L. Lund,et al.  No Effect of NGAL/lipocalin-2 on Aggressiveness of Cancer in the MMTV-PyMT/FVB/N Mouse Model for Breast Cancer , 2012, PloS one.

[10]  A. Takahashi,et al.  Therapeutic strategies for head and neck cancer based on p53 status. , 2012, Experimental and therapeutic medicine.

[11]  M. Zanetti,et al.  Lipocalin 2 in cancer: when good immunity goes bad. , 2012, Cancer letters.

[12]  Yun Wu,et al.  Relationships of lipocalin 2 with breast tumorigenesis and metastasis , 2011, Journal of cellular physiology.

[13]  T. Mak,et al.  Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. , 2010, The Journal of clinical investigation.

[14]  H. Brenner,et al.  Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. , 2010, The oncologist.

[15]  R. Tohtong,et al.  NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation , 2010, Clinical & Experimental Metastasis.

[16]  J. Cowland,et al.  Induction of Neutrophil Gelatinase-associated Lipocalin Expression by Co-stimulation with Interleukin-17 and Tumor Necrosis Factor-α Is Controlled by IκB-ζ but neither by C/EBP-β nor C/EBP-δ* , 2010, The Journal of Biological Chemistry.

[17]  T. Mak,et al.  Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis , 2010, Proceedings of the National Academy of Sciences.

[18]  G. Rice,et al.  Neutrophil gelatinase‐associated lipocalin (NGAL) an early‐screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor‐induced epithelio‐mesenchymal transition , 2007, International journal of cancer.

[19]  Zhong-ying Shen,et al.  Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion , 2006, Journal of Clinical Pathology.

[20]  D. Ovcharenko,et al.  Neutrophil gelatinase-associated lipocalin as a survival factor. , 2005, The Biochemical journal.

[21]  Li Yan,et al.  The Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Plays a Role in Breast Tumor Growth and Is Present in the Urine of Breast Cancer Patients , 2005, Clinical Cancer Research.

[22]  R. Strong,et al.  The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. , 2002, Molecular cell.

[23]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[24]  T. Kaçan,et al.  Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[25]  E. Li,et al.  Shortest path analyses in the protein-protein interaction network of NGAL (neutrophil gelatinase-associated lipocalin) overexpression in esophageal squamous cell carcinoma. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[26]  A. Leonardi,et al.  NGAL controls the metastatic potential of anaplastic thyroid carcinoma cells. , 2013, The Journal of clinical endocrinology and metabolism.